Coeptis Therapeutics Holdings, Inc. (COEP)Healthcare | Biotechnology | Wexford, United States | NasdaqCM
14.65 USD
+0.94
(6.856%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 14.80 +0.15 (1.025%) ⇧ (April 17, 2026, 7:15 p.m. EDT) Short-term: ★☆☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 11, 2026, 4:14 p.m. EDT
COEP is a highly volatile biotechnology stock with a negative beta, indicating it moves inversely to the market. The recent price history shows significant fluctuations, with a current price of $11.95, below the 52-week low of $6.26. The stock is currently trading below both the 50-day and 200-day moving averages, suggesting a bearish trend. The forward PE ratio is negative, indicating potential earnings issues, and the company is not currently paying dividends. The forecasting model suggests a slight downward trend in the next 45 days, with a low probability of reliability due to high heteroscedasticity and low p-values. Long-term investors should be cautious, as the company's fundamentals are weak, with negative earnings and a high debt-to-equity ratio. Overall, this stock is not recommended for short-term or long-term investment at this time. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.091325 |
| AutoARIMA | 0.111864 |
| MSTL | 0.117926 |
| AutoETS | 0.121135 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 69% |
| H-stat | 1.43 |
| Ljung-Box p | 0.001 |
| Jarque-Bera p | 0.668 |
| Excess Kurtosis | -0.51 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 1.911 |
| Revenue per Share | 0.322 |
| Market Cap | 91,170,184 |
| Forward P/E | -86.18 |
| Beta | -0.43 |
| Website | https://coeptistx.com |
| Attribute | Value |
|---|---|
| 52 Week Change | 0.30861998 |
| Address1 | 105 Bradford Rd |
| Address2 | Suite 420 |
| All Time High | 428.4 |
| All Time Low | 2.31 |
| Ask | 13.92 |
| Ask Size | 1 |
| Average Daily Volume10 Day | 50,860 |
| Average Daily Volume3 Month | 49,122 |
| Average Volume | 49,122 |
| Average Volume10Days | 50,860 |
| Beta | -0.429 |
| Bid | 11.8 |
| Bid Size | 2 |
| Book Value | 2.36 |
| City | Wexford |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 14.65 |
| Current Ratio | 4.157 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 14.71 |
| Day Low | 13.99 |
| Debt To Equity | 1.911 |
| Display Name | Coeptis Therapeutics |
| Dividend Date | 1,596,672,000 |
| Ebitda | -11,862,286 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -7.216 |
| Enterprise To Revenue | 62.796 |
| Enterprise Value | 85,594,328 |
| Eps Forward | -0.17 |
| Eps Trailing Twelve Months | -2.81 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 11.8628 |
| Fifty Day Average Change | 2.7872 |
| Fifty Day Average Change Percent | 0.23495297 |
| Fifty Two Week Change Percent | 30.861998 |
| Fifty Two Week High | 21.41 |
| Fifty Two Week High Change | -6.76 |
| Fifty Two Week High Change Percent | -0.31574032 |
| Fifty Two Week Low | 6.26 |
| Fifty Two Week Low Change | 8.389999 |
| Fifty Two Week Low Change Percent | 1.3402555 |
| Fifty Two Week Range | 6.26 - 21.41 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,608,215,400,000 |
| Float Shares | 5,253,083 |
| Forward Eps | -0.17 |
| Forward P E | -86.17647 |
| Free Cashflow | -3,030,945 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 4 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.86748004 |
| Gross Profits | 1,182,420 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.13641 |
| Held Percent Institutions | 0.08998 |
| Implied Shares Outstanding | 6,223,221 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,735,603,200 |
| Last Split Factor | 1:20 |
| Long Business Summary | Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, operates as a biopharmaceutical and technology company. The company is developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its therapeutic portfolio includes an allogeneic cellular immunotherapy platform; and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. The company's product pipeline consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; CD38-Diagnostic, an in vitro screening tool to analyze cancer patients if cancer patients might be appropriate candidates for anti-CD38 mAb therapy; and SNAP-CAR, a chimeric antigen receptor (CAR) therapy for treatment for cancer. In addition, the company offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania. |
| Long Name | Coeptis Therapeutics Holdings, Inc. |
| Market | us_market |
| Market Cap | 91,170,184 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_593091629 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -11,917,015 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 90,796,794 |
| Open | 13.99 |
| Operating Cashflow | -8,603,036 |
| Operating Margins | -2.3064501 |
| Payout Ratio | 0.0 |
| Phone | (724) 934-6467 |
| Post Market Change | 0.15010071 |
| Post Market Change Percent | 1.0245782 |
| Post Market Price | 14.8001 |
| Post Market Time | 1,776,467,749 |
| Previous Close | 13.71 |
| Price Hint | 2 |
| Price To Book | 6.2076273 |
| Price To Sales Trailing12 Months | 66.88714 |
| Profit Margins | 0.0 |
| Quick Ratio | 3.596 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.94 |
| Regular Market Change Percent | 6.85631 |
| Regular Market Day High | 14.71 |
| Regular Market Day Low | 13.99 |
| Regular Market Day Range | 13.99 - 14.71 |
| Regular Market Open | 13.99 |
| Regular Market Previous Close | 13.71 |
| Regular Market Price | 14.65 |
| Regular Market Time | 1,776,456,001 |
| Regular Market Volume | 42,493 |
| Return On Assets | -0.65055 |
| Return On Equity | -1.36905 |
| Revenue Per Share | 0.322 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 6,223,221 |
| Shares Percent Shares Out | 0.060500003 |
| Shares Short | 376,288 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 428,755 |
| Short Name | Coeptis Therapeutics Holdings, |
| Short Percent Of Float | 0.07 |
| Short Ratio | 7.94 |
| Source Interval | 15 |
| State | PA |
| Symbol | COEP |
| Total Cash | 6,350,898 |
| Total Cash Per Share | 1.021 |
| Total Debt | 268,875 |
| Total Revenue | 1,363,045 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.81 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 13.38895 |
| Two Hundred Day Average Change | 1.2610493 |
| Two Hundred Day Average Change Percent | 0.09418582 |
| Type Disp | Equity |
| Volume | 42,493 |
| Website | https://coeptistx.com |
| Zip | 15,090 |